MA31890B1 - Anticorps specifiques de la forme de protofibrille de proteine beta - amyloide - Google Patents
Anticorps specifiques de la forme de protofibrille de proteine beta - amyloideInfo
- Publication number
- MA31890B1 MA31890B1 MA32845A MA32845A MA31890B1 MA 31890 B1 MA31890 B1 MA 31890B1 MA 32845 A MA32845 A MA 32845A MA 32845 A MA32845 A MA 32845A MA 31890 B1 MA31890 B1 MA 31890B1
- Authority
- MA
- Morocco
- Prior art keywords
- amyloid
- peptide
- isolated antibodies
- protofibrille
- beta
- Prior art date
Links
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title abstract 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Psychiatry (AREA)
Abstract
L'invention concerne des anticorps isolés caractérisés qui présentent une affinité spécifique pour un épitope conformationnel de répétition d'une forme de protofibrille du peptide b-amyloïde humain par comparaison à des formes à bas poids moléculaire de peptide b-amyloïde. Ces anticorps isolés et compositions pharmaceutiquement efficaces apparentées peuvent être utiles pour le traitement thérapeutique et/ou préventif de la maladie d'alzheimer en bloquant efficacement la capacité de la forme de protofibrille du peptide b-amyloïde de produire des formes de fibrille liées aux complications associées à la maladie d'alzheimer. Les anticorps isolés de la présente invention sont également utiles pour divers essais de diagnostic et kits associés.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98848107P | 2007-11-16 | 2007-11-16 | |
| US1974708P | 2008-01-08 | 2008-01-08 | |
| PCT/US2008/083659 WO2009065054A2 (fr) | 2007-11-16 | 2008-11-14 | Anticorps spécifiques de la forme de protofibrille de protéine bêta-amyloïde |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA31890B1 true MA31890B1 (fr) | 2010-12-01 |
Family
ID=40639468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA32845A MA31890B1 (fr) | 2007-11-16 | 2010-05-17 | Anticorps specifiques de la forme de protofibrille de proteine beta - amyloide |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US8470321B2 (fr) |
| EP (2) | EP2207568B1 (fr) |
| JP (3) | JP5616230B2 (fr) |
| KR (3) | KR101478995B1 (fr) |
| CN (1) | CN102006887B (fr) |
| AU (1) | AU2008322523B2 (fr) |
| BR (1) | BRPI0819312A2 (fr) |
| CA (1) | CA2705582A1 (fr) |
| CO (1) | CO6270277A2 (fr) |
| CR (1) | CR11350A (fr) |
| CY (1) | CY1119376T1 (fr) |
| DK (1) | DK2207568T3 (fr) |
| DO (1) | DOP2010000097A (fr) |
| EA (1) | EA201000809A1 (fr) |
| ES (1) | ES2639016T3 (fr) |
| HK (1) | HK1244823A1 (fr) |
| HR (1) | HRP20171292T1 (fr) |
| HU (1) | HUE033825T2 (fr) |
| IL (1) | IL204542A (fr) |
| LT (1) | LT2207568T (fr) |
| MA (1) | MA31890B1 (fr) |
| ME (1) | ME01026B (fr) |
| MX (2) | MX2010003828A (fr) |
| MY (1) | MY158903A (fr) |
| NI (1) | NI201000046A (fr) |
| NZ (1) | NZ583632A (fr) |
| PL (1) | PL2207568T3 (fr) |
| PT (1) | PT2207568T (fr) |
| SG (1) | SG2014011183A (fr) |
| SI (1) | SI2207568T1 (fr) |
| TN (1) | TN2010000128A1 (fr) |
| WO (1) | WO2009065054A2 (fr) |
| ZA (1) | ZA201002592B (fr) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| NO347079B1 (no) | 2006-03-23 | 2023-05-08 | Bioarctic Neuroscience Ab | Forbedrede protofibrilselektive antistoffer og anvendelse derav |
| HRP20140049T1 (hr) | 2007-01-05 | 2014-02-28 | University Of Zürich | Anti beta-amiloid antitijela i njihova upotreba |
| EP3239174A1 (fr) * | 2007-01-05 | 2017-11-01 | University of Zurich | Anticorps anti-amyloide et son utilisation |
| EP2207568B1 (fr) | 2007-11-16 | 2017-05-31 | The Rockefeller University | Anticorps spécifiques de la forme de protofibrille de protéine bêta-amyloïde |
| JP5810413B2 (ja) | 2008-12-19 | 2015-11-11 | バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー | ヒト抗アルファシヌクレイン自己抗体 |
| FR2945538B1 (fr) * | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| EP3892633A1 (fr) * | 2009-06-29 | 2021-10-13 | BioArctic AB | Anticorps sélectifs pour des protofibrilles/oligomères à bêta-amyloïdes tronqués à leur extrémité n-terminale |
| US10266585B2 (en) | 2009-08-28 | 2019-04-23 | The Board Of Regents Of The Univerity Of Texas System | Methods of treating brain injury |
| CN102695546B (zh) | 2009-09-11 | 2014-09-10 | 前体生物药物股份公司 | 作为谷氨酰胺酰环化酶抑制剂的杂环衍生物 |
| EP2595644B1 (fr) | 2010-07-23 | 2016-03-30 | Gwangju Institute of Science and Technology | Clairance d'amyloïde bêta |
| EP2627357B1 (fr) * | 2010-10-15 | 2017-05-03 | The Board of Regents of The University of Texas System | Anticorps qui lient des oligomères amyloïdes |
| AR085302A1 (es) | 2011-02-24 | 2013-09-18 | Sanofi Sa | Metodo de produccion de anticuerpos sialilados |
| HUE041391T2 (hu) | 2011-06-23 | 2019-05-28 | Biogen Int Neuroscience Gmbh | Anti-alfa-szinukleinkötõ molekulák |
| WO2013075740A1 (fr) | 2011-11-23 | 2013-05-30 | Sanofi | Procédé de purification d'anticorps |
| JP2013159596A (ja) * | 2012-02-08 | 2013-08-19 | Nihon Univ | β−アミロイド前駆体タンパク質のマイクロ凝集体に特異的なモノクローナル抗体 |
| US9617332B2 (en) * | 2012-05-10 | 2017-04-11 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Conformational-specific antibodies against A[β] oligomers |
| EP2674495A1 (fr) | 2012-06-14 | 2013-12-18 | Sanofi | Système d'expression dans CHO |
| JP6463734B2 (ja) | 2013-05-06 | 2019-02-06 | サノフイＳａｎｏｆｉ | 抗体を精製するための連続的多工程法 |
| US10035847B2 (en) | 2013-10-02 | 2018-07-31 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
| JP6628786B2 (ja) * | 2014-07-10 | 2020-01-15 | バイオアークティック アーベー | 改善されたＡβプロトフィブリル結合抗体 |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| US10772969B2 (en) | 2015-11-09 | 2020-09-15 | The University Of British Columbia | N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto |
| KR20180094876A (ko) | 2015-11-09 | 2018-08-24 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아밀로이드 베타 에피토프 및 이에 대한 항체 |
| WO2017079834A1 (fr) * | 2015-11-09 | 2017-05-18 | The University Of British Columbia | Épitopes dans la bêta-amyloïde et anticorps conformationnels sélectifs associés |
| CA3004494A1 (fr) | 2015-11-09 | 2017-05-18 | The University Of British Columiba | Epitopes dans la region centrale de la beta-amyloide et anticorps conformationnels selectifs associes |
| DE102016005169B3 (de) * | 2016-04-29 | 2017-07-13 | Forschungszentrum Jülich GmbH | Verfahren zur Identifikation von Inhibitoren der primären Nukleation der Amyloid-Beta-Aggregation |
| AU2017299858B2 (en) | 2016-07-18 | 2024-07-25 | Promis Neurosciences, Inc. | Antibodies to Amyloid beta |
| US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
| EP3354278A1 (fr) * | 2017-01-31 | 2018-08-01 | Sanofi | Effet de protection des cellules neuronales d'anticorps spécifiques de la forme protofibrillaire du peptide bêta-amyloïde |
| US12286469B2 (en) | 2017-07-18 | 2025-04-29 | The University Of British Columbia | Humanized antibodies binding to amyloid-beta (A-beta) |
| EP3658172A4 (fr) | 2017-07-25 | 2021-05-05 | TrueBinding, Inc. | Traitement du cancer par blocage de l'interaction de tim-3 et de son ligand |
| WO2019040612A1 (fr) | 2017-08-22 | 2019-02-28 | Biogen Ma Inc. | Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| US11953502B2 (en) * | 2017-10-12 | 2024-04-09 | E&S Healthcare Co., Ltd. | Thioredoxin 1 epitope, encoding nucleic acid and methods of binding a monoclonal antibody |
| KR102523019B1 (ko) * | 2018-05-30 | 2023-04-18 | 내셔날 헬스 리서치 인스티튜트 | 항-a베타 항체 및 이의 용도 |
| WO2020144233A1 (fr) | 2019-01-09 | 2020-07-16 | Vect-Horus | Molécules de liaison au récepteur de transferrine, leurs conjugués et leurs utilisations |
| CN120058944A (zh) | 2019-01-30 | 2025-05-30 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| TW202110878A (zh) | 2019-05-16 | 2021-03-16 | 法商賽諾菲公司 | 在神經系統中表現抗原結合蛋白 |
| JPWO2021006212A1 (fr) * | 2019-07-08 | 2021-01-14 | ||
| US20220356233A1 (en) * | 2019-08-20 | 2022-11-10 | The Curators Of The University Of Missouri | Amyloid-beta antibodies |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| JP2023535024A (ja) | 2020-07-23 | 2023-08-15 | オター プロシーナ リミテッド | 抗ａベータ抗体 |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| WO2022251048A1 (fr) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anticorps anti-amyloïde bêta et leurs utilisations |
| JP2024534269A (ja) * | 2021-08-30 | 2024-09-18 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 神経変性疾患を治療するための方法および物質 |
| CN114544940B (zh) * | 2022-02-21 | 2024-09-24 | 中国海洋大学 | 一种用于快速检测透明质酸的胶体金试纸条 |
| KR102530956B1 (ko) * | 2022-09-08 | 2023-05-11 | 주식회사 알츠코리아 | 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도 |
| CN120513256A (zh) * | 2023-01-20 | 2025-08-19 | 迈威(美国)生物治疗有限公司 | 抗淀粉样蛋白β原纤丝/低聚物抗体和其用途 |
| WO2024261333A1 (fr) | 2023-06-22 | 2024-12-26 | Vect-Horus | Molécules de liaison au récepteur de la transferrine, leurs conjugués et leurs utilisations pour prévenir ou traiter des maladies du système nerveux |
| EP4480965A1 (fr) | 2023-06-22 | 2024-12-25 | Vect-Horus | Molécules de liaison au récepteur de transferrine, leurs conjugués et leurs utilisations pour prévenir ou traiter des maladies du snc |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US4636524A (en) | 1984-12-06 | 1987-01-13 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
| US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9206318D0 (en) | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6492160B1 (en) | 1991-05-15 | 2002-12-10 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5962255A (en) | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| DE69233782D1 (de) | 1991-12-02 | 2010-05-20 | Medical Res Council | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| CA2474701C (fr) | 1993-11-19 | 2009-01-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation de microparticules biodegradables contenant un agent biologiquement actif |
| EP0977991A4 (fr) | 1997-03-03 | 2004-12-15 | Bristol Myers Squibb Co | Anticorps monoclonaux pour le cd6 humain |
| US6656508B2 (en) | 1997-04-17 | 2003-12-02 | Amgen Inc. | Sustained-release alginate gels |
| DE69839147T2 (de) | 1997-06-12 | 2009-02-19 | Novartis International Pharmaceutical Ltd. | Künstliche antikörperpolypeptide |
| JP2001522812A (ja) | 1997-11-07 | 2001-11-20 | カイロン コーポレイション | Ｉｇｆ−１持続放出性処方物の作製方法 |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
| US6451346B1 (en) | 1998-12-23 | 2002-09-17 | Amgen Inc | Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents |
| US6919075B1 (en) * | 1999-09-03 | 2005-07-19 | Ramot At Tel Aviv University Ltd. | Bacteriophage displaying aβ epitopes and method of use |
| US6953593B2 (en) | 2000-02-01 | 2005-10-11 | Lipoprotein Technologies, Inc. | Sustained-release microencapsulated delivery system |
| DE1257584T1 (de) | 2000-02-24 | 2003-05-28 | Lilly Co Eli | Humanisierte antikörper, die amyloid beta peptid demarkieren |
| PT1284998E (pt) | 2000-05-22 | 2005-06-30 | Univ New York | Eptideos imunogenicos sinteticos mas nao-amiloidogenicos homologos a beta-amiloides, destinados a induzir uma reaccao imunitaria contra os beta-amiloides e os depositos amiloides |
| EP2082749A3 (fr) | 2000-07-07 | 2010-06-30 | Bioarctic Neuroscience AB | Prévention et traitement de la maladie d'Alzheimer |
| CA2418835A1 (fr) | 2000-10-16 | 2002-04-25 | Phylos, Inc. | Echafaudages proteiniques internes pour analogues d'anticorps et autres proteines de liaison |
| WO2002053739A2 (fr) | 2000-11-15 | 2002-07-11 | Zymogenetics, Inc. | Homologue zcub5 de neuropiline |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| AU2002248792B2 (en) | 2001-04-18 | 2006-09-21 | Nostrum Pharmaceuticals Inc. | A novel coating for a sustained release pharmaceutical composition |
| CA2478833C (fr) * | 2002-03-13 | 2015-11-10 | Biogen, Inc. | Anticorps anti-.alpha.v.beta.6 |
| CA2492671C (fr) | 2002-03-22 | 2012-04-17 | Aprogen, Inc. | Anticorps humanise et procede de preparation correspondant |
| ATE506072T1 (de) | 2002-09-12 | 2011-05-15 | Univ California | Immunogene und entsprechende antikörper, die spezifisch sind für häufige hochmolekulare aggregations-zwischenprodukte von amyloiden aus proteinen unterschiedlicher sequenz |
| US7063725B2 (en) | 2002-10-21 | 2006-06-20 | Sdgi Holdings, Inc. | Systems and techniques for restoring and maintaining intervertebral anatomy |
| US20040223970A1 (en) * | 2003-02-28 | 2004-11-11 | Daniel Afar | Antibodies against SLC15A2 and uses thereof |
| US20050124016A1 (en) | 2003-08-01 | 2005-06-09 | Enh Research Institute | Antibodies specific for toxic amyloid beta protein oligomers |
| CA2437639C (fr) | 2003-08-11 | 2016-07-05 | Valera Pharmaceuticals, Inc. | Dispositifs de distribution de medicaments a long terme dotes de polymeres a base de polyurethane et leur fabrication |
| US20070110750A1 (en) | 2003-09-12 | 2007-05-17 | The Regents Of The University Of California | Monoclonal antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence |
| US20050187631A1 (en) | 2004-01-27 | 2005-08-25 | Sdgi Holdings, Inc. | Prosthetic device |
| SE0401601D0 (sv) * | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| CA2593846A1 (fr) | 2005-01-14 | 2006-08-10 | The Regents Of The University Of California | Compositions et methodes d'inhibition de la formation de drusen et methodes de diagnostic ou de traitement de pathologies liees aux drusen |
| AU2006208226A1 (en) | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
| WO2007022416A2 (fr) * | 2005-08-18 | 2007-02-22 | Ramot At Tel Aviv University Ltd. | Anticorps monocatenaires diriges contre le peptide $g(b)-amyloide |
| KR101439828B1 (ko) | 2005-11-30 | 2014-09-17 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
| NO347079B1 (no) * | 2006-03-23 | 2023-05-08 | Bioarctic Neuroscience Ab | Forbedrede protofibrilselektive antistoffer og anvendelse derav |
| SG182192A1 (en) | 2007-06-12 | 2012-07-30 | Ac Immune Sa | Humanized antibodies to amyloid beta |
| EP2207568B1 (fr) | 2007-11-16 | 2017-05-31 | The Rockefeller University | Anticorps spécifiques de la forme de protofibrille de protéine bêta-amyloïde |
| FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
-
2008
- 2008-11-14 EP EP08849467.9A patent/EP2207568B1/fr not_active Not-in-force
- 2008-11-14 ES ES08849467.9T patent/ES2639016T3/es active Active
- 2008-11-14 MX MX2010003828A patent/MX2010003828A/es active IP Right Grant
- 2008-11-14 MY MYPI2010001497A patent/MY158903A/en unknown
- 2008-11-14 CA CA2705582A patent/CA2705582A1/fr not_active Abandoned
- 2008-11-14 KR KR1020137010598A patent/KR101478995B1/ko not_active Expired - Fee Related
- 2008-11-14 WO PCT/US2008/083659 patent/WO2009065054A2/fr not_active Ceased
- 2008-11-14 BR BRPI0819312-6A patent/BRPI0819312A2/pt not_active Application Discontinuation
- 2008-11-14 NZ NZ583632A patent/NZ583632A/en not_active IP Right Cessation
- 2008-11-14 CN CN200880116438.9A patent/CN102006887B/zh not_active Expired - Fee Related
- 2008-11-14 HU HUE08849467A patent/HUE033825T2/en unknown
- 2008-11-14 KR KR1020147029636A patent/KR101581733B1/ko not_active Expired - Fee Related
- 2008-11-14 AU AU2008322523A patent/AU2008322523B2/en not_active Ceased
- 2008-11-14 SI SI200831857T patent/SI2207568T1/sl unknown
- 2008-11-14 EA EA201000809A patent/EA201000809A1/ru unknown
- 2008-11-14 JP JP2010534239A patent/JP5616230B2/ja not_active Expired - Fee Related
- 2008-11-14 EP EP17173145.8A patent/EP3257865A1/fr not_active Withdrawn
- 2008-11-14 PT PT88494679T patent/PT2207568T/pt unknown
- 2008-11-14 SG SG2014011183A patent/SG2014011183A/en unknown
- 2008-11-14 US US12/738,955 patent/US8470321B2/en not_active Expired - Fee Related
- 2008-11-14 KR KR1020107011148A patent/KR101377535B1/ko not_active Expired - Fee Related
- 2008-11-14 HR HRP20171292TT patent/HRP20171292T1/hr unknown
- 2008-11-14 MX MX2012010835A patent/MX335965B/es unknown
- 2008-11-14 DK DK08849467.9T patent/DK2207568T3/en active
- 2008-11-14 LT LTEP08849467.9T patent/LT2207568T/lt unknown
- 2008-11-14 ME MEP-2010-76A patent/ME01026B/fr unknown
- 2008-11-14 PL PL08849467T patent/PL2207568T3/pl unknown
-
2010
- 2010-03-16 IL IL204542A patent/IL204542A/en active IP Right Grant
- 2010-03-22 TN TNP2010000128A patent/TN2010000128A1/fr unknown
- 2010-04-07 DO DO2010000097A patent/DOP2010000097A/es unknown
- 2010-04-07 CR CR11350A patent/CR11350A/es unknown
- 2010-04-07 CO CO10039830A patent/CO6270277A2/es not_active Application Discontinuation
- 2010-04-07 NI NI201000046A patent/NI201000046A/es unknown
- 2010-04-14 ZA ZA2010/02592A patent/ZA201002592B/en unknown
- 2010-05-17 MA MA32845A patent/MA31890B1/fr unknown
-
2011
- 2011-01-21 HK HK18104106.3A patent/HK1244823A1/en unknown
-
2013
- 2013-05-28 US US13/903,081 patent/US9340607B2/en not_active Expired - Fee Related
-
2014
- 2014-06-30 JP JP2014135187A patent/JP2014223074A/ja active Pending
-
2016
- 2016-05-16 US US15/155,275 patent/US20160319006A1/en not_active Abandoned
-
2017
- 2017-08-30 CY CY20171100918T patent/CY1119376T1/el unknown
-
2018
- 2018-03-22 JP JP2018054674A patent/JP2018140988A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA31890B1 (fr) | Anticorps specifiques de la forme de protofibrille de proteine beta - amyloide | |
| TW264480B (fr) | ||
| WO2003016466A3 (fr) | Anticorps anti-$g(a)$g(b) | |
| EP2292649A3 (fr) | Epitopes thérapeutiques et leurs utilisations | |
| TW200718710A (en) | Antibodies directed against amyloid-beta peptide and methods using same | |
| EA200400162A1 (ru) | N-(3-амино-2-гидроксипропил)замещенные алкиламидные соединения | |
| GB2364059A (en) | Beta-Secretase enzyme compositions and methods | |
| TW200732348A (en) | Monoclonal antibody | |
| MX2022005782A (es) | Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos. | |
| WO2002046222A3 (fr) | Compositions et procede de diagnostic de la maladie d'alzheimer | |
| BR0214705A (pt) | Composição, seu uso, método para prevenção ou tratamento de doença neurodegenerativa, e kit | |
| WO2007087151A3 (fr) | Méthode de traitement d'un dysfonctionnement cognitif | |
| WO2004062625A3 (fr) | Inhibiteurs de beta-secretase macrocyclique pour traiter la maladie d'alzheimer | |
| WO2005105129A3 (fr) | Epitopes associes a une maladie coeliaque | |
| WO2005018545A3 (fr) | Inhibiteurs macrocycliques de la beta-secretase destines au traitement de la maladie d'alzheimer | |
| BRPI0410049A (pt) | composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, uso de um composto, composição farmacêutica, e, kit farmacêutico | |
| WO2004064869A3 (fr) | Agent de chelation metallique, a liaison amyloide | |
| EA200800880A1 (ru) | Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции | |
| WO2007140011A3 (fr) | Cellules progénitrices érythroïdes et procédés de production du parvovirus b19 dans ces cellules | |
| WO2008057599A3 (fr) | Procédés de traitement de troubles associés à l'abeta et compositions | |
| WO2008070284A3 (fr) | Peptides bêta amyloïdes et procédés d'utilisations de ceux-ci | |
| IL172229A (en) | Use of pyrzolopyridines for the preparation of medicinal products to improve cognitive perception | |
| EP1867337A4 (fr) | Composition médicinale pour traiter/prévenir la maladie d'organes moteurs | |
| NO20065196L (no) | Terapeutisk kombinasjon for behandling av Alzheimers sykdom | |
| HK40098773A (en) | Compositions and methods for the treatment of alzheimer's disease |